University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
USDA National Wildlife Research Center - Staff
Publications

U.S. Department of Agriculture: Animal and Plant
Health Inspection Service

2017

Evaluation of antibody response to an adjuvanted
hapten-protein vaccine as a potential inhibitor of
sexual maturation for farmed Atlantic salmon
Darcy S.O. Mora
USDA National Wildlife Research Center, dmora@sivecbiotech.com

Mo D. Salman
Colorado State University, mo.salman@colostate.edu

Christopher A. Myrick
Colorado State University, chris.myrick@colostate.edu

Jack C. Rhyan
USDA National Wildlife Research Center, jack.c.rhyan@aphis.usda.gov

Lowell A. Miller
Circle M Products, lowell@circlemproducts.com
See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc
Part of the Life Sciences Commons
Mora, Darcy S.O.; Salman, Mo D.; Myrick, Christopher A.; Rhyan, Jack C.; Miller, Lowell A.; Sætre, Ellen Marie; and Eckery, Douglas
C., "Evaluation of antibody response to an adjuvanted hapten-protein vaccine as a potential inhibitor of sexual maturation for farmed
Atlantic salmon" (2017). USDA National Wildlife Research Center - Staff Publications. 2065.
https://digitalcommons.unl.edu/icwdm_usdanwrc/2065

This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff Publications
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Darcy S.O. Mora, Mo D. Salman, Christopher A. Myrick, Jack C. Rhyan, Lowell A. Miller, Ellen Marie Sætre,
and Douglas C. Eckery

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/icwdm_usdanwrc/
2065

U.S. Department of Agriculture
Animal and Plant Health Inspection Service
Wildlife Services

U.S. Government Publication

Fish & Shellﬁsh Immunology 71 (2017) 255e263

Contents lists available at ScienceDirect

Fish & Shellﬁsh Immunology
journal homepage: www.elsevier.com/locate/fsi

Full length article

Evaluation of antibody response to an adjuvanted hapten-protein
vaccine as a potential inhibitor of sexual maturation for farmed
Atlantic salmon
Darcy S.O. Mora a, Mo D. Salman b, Christopher A. Myrick c, Jack C. Rhyan d,
Lowell A. Miller e, Ellen Marie Sætre f, Douglas C. Eckery a, *
a

United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center, 4101 LaPorte
Avenue, Fort Collins, CO 80521, USA
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Colorado State University, 300 W Drake Road, Fort Collins, CO
80525, USA
c
Department of Fish, Wildlife, and Conservation Biology, Warner College of Natural Resources, Colorado State University, 1474 Campus Delivery, Fort Collins,
CO 80523, USA
d
United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, National Wildlife Research Center, 4101 LaPorte
Avenue, Fort Collins, CO 80521, USA
e
Circle M Products, 12242 County Rd 66, Greeley, CO 80631, USA
f
Daugstad, 6392 Vikebukt, Norway
b

a r t i c l e i n f o

a b s t r a c t

Article history:
Received 24 April 2017
Received in revised form
28 July 2017
Accepted 29 August 2017
Available online 31 August 2017

An experimental contraceptive vaccine was evaluated in Atlantic salmon (Salmo salar). A peptide derived
from the beta subunit of luteinizing hormone (LH) was conjugated to two different carrier proteins,
bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH), and formulated with one of four
immunostimulants in a water-in-oil emulsion. Speciﬁc antibody responses to the peptide and each
carrier protein were evaluated. While the antibody response to KLH was stronger than the response to
BSA, both carrier proteins stimulated comparable antibody responses to the LH peptide. The immunostimulant proved to be more important for enhancing the LH peptide antibody response than the
carrier protein selection; vaccines containing a combination of Aeromonas salmonicida and Vibrio
anguillarum stimulated signiﬁcantly greater LH peptide antibody production than any of the other three
immunostimulants evaluated at 12 weeks post-vaccination. This study provides proof-of-concept for
speciﬁc antibody production against a hapten-carrier protein antigen in Atlantic salmon and reinforces
the importance of vaccine immunostimulant selection.
© 2017 Published by Elsevier Ltd.
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Aquaculture is the fastest growing food-animal producing sector
[1] and provides 47% of ﬁsh for human consumption [2]. The United
Nations Food and Agriculture Association (FAO) predicts that the
global demand for seafood will increase 25% through 2030. As wild
ﬁsh stocks have diminished and food security continues to be a
global issue, sustainable ﬁsh farming practices are of increasing
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importance and are being heavily scrutinized by governmental and
environmental agencies.
More than 14% of ﬁsh produced globally are salmonids [2]. With
aquaculture production of salmonids expanding at an average
annual rate of nearly 10% [2], there is an increasing risk of farmed
salmon inadvertently escaping into bodies of water inhabited by
wild ﬁsh populations [3e6]. Farmed salmon all originate from a
limited set of lineages and have substantially reduced genetic diversity due to founder effects, and other selection-related factors
[7]. Asynchrony in release of sperm and eggs, a lack of dominance
relationships among males, indiscriminate aggression, and various
other behavioral dynamics lead to reduced reproductive success in
farmed Atlantic salmon [8,9]. Despite the reduced breeding performance of escaped farmed salmon, they are still able to breed
with wild salmon, thereby altering the genetics of those unique
wild populations and negatively affecting population survival
[7,9e12]. Even sterile, induced-triploid male Atlantic salmon have
been observed to exhibit spawning behaviors and induce wild females to spawn in the absence of a wild male [13], potentially
affecting seasonal reproductive success.
Immunocontraception could provide a means to prevent
escaped salmon from cross-breeding with wild salmon. If administered at the proper stage in a ﬁsh's development, a contraceptive
vaccine could also potentially prevent ﬁsh from sexually maturing
[14].
Gonadotropin releasing hormone (GnRH) is an important
regulator of sexual maturation and reproduction. Two forms of
GnRH are synthesized in the hypothalamus and transported via
neurons to the pituitary [15e18]. In the pituitary, GnRH stimulates
secretion of two protein hormones, gonadotropin I (GTH-I) and
gonadotropin II (GTH-II), also known as follicle stimulating hormone (FSH) and lutenizing hormone (LH) respectively, which are
carried to gonads in the bloodstream [15,19]. The primary role of
FSH in ﬁsh is to stimulate gonad development, while both FSH and
LH regulate functions of the mature reproductive system, such as
ovulation and sperm release [20,21]. FSH and LH both consist of an
alpha subunit, necessary for structural integrity, and a beta subunit,
which is the biologically active portion of the molecule [14].
Vaccination against selected infectious diseases in large-scale
aquaculture operations is standard practice, especially for highvalue species like Atlantic salmon [22]. Both adaptive and innate
immune responses are observed in teleosts [23], though the innate
system is thought to be more highly developed [24]. Most aquaculture vaccine antigens are poorly immunogenic on their own and
require modiﬁcation or formulation with an adjuvant to sufﬁciently
excite the immune system [22,25].
Thus, as both endogenous and very small molecules, most
reproductive peptides in a vaccine would fail to elicit any sort of
immune response. Large foreign molecules such as keyhole limpet
hemocyanin (KLH) and bovine serum albumin (BSA) are easily
identiﬁed as non-self and are useful for increasing immunogenicity
of small or minimally immunogenic antigens [26]. KLH and BSA are
readily taken up by antigen presenting cells (APCs) in teleosts
[26e28] and aid in antigen uptake by recruiting T-helper cells [29]
which make them well suited as carrier proteins.
Oil-based adjuvants may prolong the duration of antigen presentation due to a depot effect [22] wherein clearance of the antigen from the injection site is slowed [29]. Antigen uptake is also
facilitated by oil-adjuvanted vaccines through varying degrees of
tissue damage at the vaccine injection site [30]. Water-in-oil
emulsions are the most common form of oil-adjuvanted vaccines.
Other adjuvants, referred to as immunostimulants, stimulate
non-speciﬁc immune responses and often amplify speciﬁc immune
responses, thereby improving potency and efﬁcacy [26,31]. This is
usually accomplished via enhanced antigen presentation or

stability [32], immunomodulation [29], or by eliciting easily
recognized ‘danger’ signals that stimulate immune system activation [30].
Toll-like receptors and pattern recognition receptors bind a
wide range of molecules exhibiting conserved pathogen-associated
molecular patterns (PAMPs) [30], such as muramyl dipeptide (MDP)
[33,34] and beta-glucans derived from yeast and fungi. These
compounds are proven immunostimulants and immunomodulators in ﬁsh vaccines [29,34]. Bacteria are often an antigen in
aquaculture vaccines and are not conventionally classiﬁed as
immunostimulants. However, bacteria can act as an adjuvant when
mixed with protein antigens by inducing macrophages to stimulate
differentiation and proliferation of T cells speciﬁc to the protein
antigen [35]. In this manuscript, we will refer to bacteria included
in vaccine as an ‘immunostimulant’ due to its intended purpose as
adjuvant rather than antigen.
This manuscript reports the ﬁndings from a study that was
conducted to evaluate antibody production in Atlantic salmon
injected with experimental vaccine formulations containing a LH
peptide conjugated to a carrier protein. The purposes of this study
were to: 1) assess the feasibility of stimulating antibody production
against an endogenous reproductive peptide, 2) compare immunogenicity of two different carrier proteins, 3) determine which of
four immunostimulants is most efﬁcient at exciting non-speciﬁc
antibody production, and 4) evaluate the suitability of a particular oil adjuvant for use in Atlantic salmon.
2. Materials and methods
2.1. Fish
Atlantic salmon (n ¼ 503; Bolaks breed), hatched at the Noﬁma
Marin Sunndalsøra Research Station (Sunndalsøra, Norway), were
used in this study. Upon study initiation, mean ﬁsh weight was
approximately 174 g (±1.2 g), smoltiﬁcation was underway but
incomplete, and none of the ﬁsh had received any other vaccinations. After three weeks in quarantine, acclimation to the housing
conditions and smoltiﬁcation were complete. The salmon were
anesthetized in a 50 mg/L solution of Finquel®/MS-222 (tricaine
methanesulfonate) (Scan Aqua AS; Hvam, Norway), and a passive
integrated transponder (PIT tag) was inserted in the ventral area of
the abdominal cavity (fatty tissue posterior to the pyloric ceca) for
unique identiﬁcation.
2.2. Rearing conditions
Vaccine trials were conducted at Noﬁma Marin facilities in
Sunndalsøra, Norway in eight 250-L indoor tanks. The salmon were
sustained on a diet of Nutra Olympic feed (3 mm; Skretting; Stavanger, Norway) provided by an automatic feeding system. Using a
random number generator, each salmon was randomly assigned to
one of nine treatment groups (55e56 ﬁsh per treatment group) and
randomly assigned to one of eight tanks (62e63 ﬁsh per tank).
Water temperature was maintained between 8 and 9  C for the
duration of the study.
2.3. Vaccines
There is wide agreement in the literature that intraperitoneal
vaccination with 100e200 mL of oil-adjuvanted vaccine is appropriate for immunocompetent salmonids [27,36,37].
2.3.1. Vaccine compositions
Eight different contraceptive vaccine formulations (treatments
1e8) and a control vaccine (treatment 0) were manufactured in a
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cleanroom at the National Wildlife Research Center (Fort Collins,
Colorado, USA). All vaccines (except the control) contained
0.222 mg/mL of an 18 amino acid peptide derived from the beta
subunit of the salmon LH protein (referred to as LH-b peptide
herein) (GL Biochem (Shanghai) Ltd.; Shanghai, China). The peptide
was conjugated to a carrier protein, either BSA or KLH (Thermo
Fisher Scientiﬁc; Waltham, Massachusetts), per the carrier protein
manufacturer recommendations. Brieﬂy, for each vaccine formulation, 10 mg of maleimide-activated BSA or KLH was incubated
with 8 mg of LH-b peptide in 3 mL of 0.03 M phosphate buffered
saline (PBS) at 24  C for 2 h. The conjugate was incorporated in the
vaccines at a ﬁnal concentration of 0.50 mg/mL [27,38,39]. Each
vaccine also contained one of four immunostimulants at a concentration of 0.50 mg/mL or 8.3  104 cells/mL, including muramyl
dipeptide, beta glucans, killed Aeromonas salmonicida and Vibrio
anguillarum mixture, and killed Mycobacterium marinum.
2.3.2. Immunostimulant preparation
Ac-muramyl-Ala-D-Glu-NH2 muramyl dipeptide (MDP) was
sourced from Bachem Americas, Inc. (Torrance, California) and used
without modiﬁcation.
MacroGard® puriﬁed beta-1,3/1,6-glucans (Biorigin Europe;
Antwerp, Belgium) was treated for 20 min at 80  C to inactivate
bacterial and fungal constituents. Once cooled, it was resuspended
at 9 mg/mL in sterile 0.01 M PBS on ice and sonicated for 30 s twice
to minimize clumping.
Mycobacterium marinum ATCC® 927™ was cultured on Middlebrook and Cohn 7H10 agar slants (BD Diagnostic Systems;
Sparks, Maryland) at 30  C for 9 days. A single colony of M. marinum
was then inoculated into 50 mL of pre-warmed Middlebrook 7H9
broth with glycerol and ADC enrichment in a sterile 250 mL culture
ﬂask and incubated with continuous shaking for 23 days in the
dark. Once conﬂuent and in the late log-phase of growth (3 passages), the cells were heated at 121  C for 30 min. Approximately
45 mL of the killed cell suspension was centrifuged for 10 min at
2500g. The supernatant was aspirated and the pelleted cells were
resuspended in 30 mL of sterile 0.01 PBS. The cells were washed
twice more and resuspended in 10 mL sterile 0.01 M PBS. The cell
suspension was passed through a 26 gauge needle three times and
then centrifuged at 100g for 2 min to recover a single-cell population. The concentration of the single-cell suspension was
determined using a Sceptre handheld automated cell counter (EMD
Millipore; Billerica, Massachusetts).
Advantigen® vaccine (Microtek International Inc.; Saanichton,
British Columbia) was used as the source of A. salmonicida and
V. anguillarum serotypes 01 and 02. The Advantigen was aliquoted
in 15 mL conical tubes and centrifuged at 4  C for 20 min at
approximately 3700g. The pelleted cells were transferred to clean
tubes, resuspended in sterile 0.01 M PBS, and centrifuged for
another 10 min. Cell concentration was again determined using a
Sceptre handheld automated cell counter (EMD Millipore).
2.3.3. Vaccine preparation
The vaccine aqueous phases, containing carrier-peptide conjugate and immunostimulant in sterile 0.01 M PBS, were combined
with Seppic Montanide™ ISA 761 VG (Air Liquide; Puteaux, France)
adjuvant (30:70 v/v) using a stand mixer with an impeller style
blade to form a water-in-oil emulsion. The primary emulsion was
passed one time through a Microﬂuidizer® Processor (Microﬂuidics
Corporation; Westwood, Massachusetts). Sterile, rubber latex-free,
single-use syringes were ﬁlled with individual doses of 0.2 mL. Each
vaccine formulation contained the same peptide, one of two carrier
proteins, and one of four immunostimulants, as designated in
Table 1 as ﬁnal concentrations.
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2.4. Sampling and vaccination
Four weeks after PIT tagging, salmon were anesthetized as
described above, and a 21 gauge needle was used to draw
0.5e1.0 mL of blood from the caudal vein. Following the blood draw,
0.2 mL of contraceptive vaccine was injected into the peritoneal
cavity of each ﬁsh. Additional blood samples were taken at 8 and 12
weeks post-vaccination. All blood samples were collected in
microcentrifuge tubes, allowed to clot at room temperature, and
then centrifuged at 1000e2000g for 10 min. Sera were transferred to clean microcentrifuge tubes and stored at 80  C until
analyzed. The weight and length of each ﬁsh were also measured at
each sampling time point. Upon study termination, the ﬁsh were
euthanized with an overdose of Finquel®.
2.5. Antibody responses
Three enzyme-linked immunosorbent assays (ELISAs) were
developed to semi-quantitatively measure the presence of antibodies speciﬁc to the vaccine components; namely the LH-b peptide, BSA, and KLH.
Due to the small molecular size of the LH-b peptide, a conjugate
was prepared for use as antigen. The LH-b peptide was conjugated
to ovalbumin (OVA) (Thermo Fisher Scientiﬁc) using SM(PEG)2
crosslinker (Thermo Fisher Scientiﬁc). Brieﬂy, 4.5 mg of ovalbumin
was reacted with 1 mmole of crosslinker for 30 min at 24  C in 1 mL
of molecular-grade water. Excess crosslinker was removed using a
Sephadex G25 column (GE Healthcare; Little Chalfont, United
Kingdom). The activated ovalbumin was then mixed with 8.3 mg of
LH-b peptide in a total volume of 4.5 mL and incubated for 30 min
at 24  C. The resulting conjugate was loaded onto two PD10
Sephadex G25 columns, each eluted with 3.5 mL of 0.1 M PBS. The
ﬁnal protein concentration of the conjugate was determined by
Bradford assay.
2.5.1. ELISA protocol
Salmon sera were diluted 1:10 in ‘milk block’ (5% w/v powdered
skim milk in 0.01 M PBS with 5% Tween 20 (Amresco; Framingham,
Massachusetts)) and stored at 4  C overnight for pre-adsorbtion of
serum antibodies [37]. 96-well high-bind polystyrene plates (Santa
Cruz Biotech; Santa Cruz, California) were coated with 50 mL of
antigen in either 0.05 M carbonate-bicarbonate buffer (SigmaAldrich; St. Louis, Missouri) or 0.01 M PBS (Sigma-Aldrich). Plates
were stored overnight at 4  C then washed three times with 200 mL
of 0.01 M PBS with 0.05% Tween 20 (PBST) (Sigma-Aldrich). Each
well was incubated with 200 mL of milk block for 1 h at 24  C. Plates
were washed three times with 200 mL PBST. Duplicate wells were
loaded with 50 mL pre-adsorbed sera and plates were incubated for
1 h at 24  C before being washed three times with 200 mL PBST.
Monoclonal mouse anti-salmonid Ig antibody conjugated to
horseradish peroxidase (HRP) (US Biological; Salem, MA) was
diluted 1:1000 in 0.01 M PBS and 50 mL was added to each well.
Plates were covered and incubated for 1 h at 24  C, then washed
three times with 200 mL wash buffer. Enzyme substrate was prepared by dissolving 1 mg of 3,30 ,5,50 -tetramethylbenzidine dihydrochloride (Sigma-Aldrich) per 10 mL of 0.05 M phosphate citrate
buffer with 0.014% hydrogen peroxide (Sigma-Aldrich). 50 mL of
enzyme substrate was added to each well and plates were incubated at 24  C for a ﬁxed time before the reaction was stopped with
50 mL of 2 M sulfuric acid and optical density was measured at a
single wavelength of 450 nm. Table 2 provides additional detail
about the variations on this generic protocol that are speciﬁc to
each antigen evaluated. All plates were run with positive control
and negative control samples, identiﬁed during assay development.
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Table 1
Comparison of Atlantic salmon contraceptive vaccine formulations.
Formulation #

Peptide

Peptide Conc. (mg/mL)

Carrier

Carrier Conc. (mg/mL)

Immunostimulant

Immunostimulant Conc.

Adjuvant

0 (sham)
1
2
3
4
5
6
7
8

none
LH-b 18mer
LH-b 18mer
LH-b 18mer
LH-b 18mer
LH-b 18mer
LH-b 18mer
LH-b 18mer
LH-b 18mer

0
0.222
0.222
0.222
0.222
0.222
0.222
0.222
0.222

none
BSA
KLH
BSA
KLH
BSA
KLH
BSA
KLH

0
0.278
0.278
0.278
0.278
0.278
0.278
0.278
0.278

none
b-glucan
b-glucan
Muramyl dipeptide
Muramyl dipeptide
A. salmonicida þ V. anguillarum
A. salmonicida þ V. anguillarum
M. marinum
M. marinum

0
0.5
0.5
0.5
0.5
8.3
8.3
8.3
8.3

ISA761
ISA761
ISA761
ISA761
ISA761
ISA761
ISA761
ISA761
ISA761

mg/mL
mg/mL
mg/mL
mg/mL
 104 cells/mL
 104 cells/mL
 104 cells/mL
 104 cells/mL

VG
VG
VG
VG
VG
VG
VG
VG
VG

Table 2
Antigen-speciﬁc modiﬁcations to the generic ELISA protocol provided for detection of antibodies to BSA, KLH, and LH in Atlantic salmon.
Antigen

Antigen Conc. (ng/mL)

Coating Buffer

Substrate Dev. (minutes)

BSA
KLH
LH-b conjugate

10
5
3.74

Carb-bicarb
Carb-bicarb
PBS

15
11
11

2.6. Statistical analyses
There were 503 ﬁsh on trial initially but some of the ﬁsh were
lost due to complications with the blood draws at each sampling
time. As such, the number of samples from each treatment group
and each time point decreased as the study progressed for a ﬁnal
count of 418 ﬁsh upon study termination, as shown in Table 3.
Antibody production was evaluated using optical densities
(ODs) measured by the ELISAs. Samples were included in the
dataset if the duplicate well ODs had a coefﬁcient of variation (CV)
less than 15%; if the CV exceeded 15% and one or both duplicate
sample ODs were greater than the assay limit of detection, the
sample was re-run.
Assay background was accounted for by subtracting the mean
OD of wells incubated with PBS instead of serum, included on every
plate. To account for inter-plate variation, results are presented as
sample to positive ratios minus the mean pre-vaccination OD for
that treatment [40e42].
A Kruskal-Wallis one-way analysis of variance (ANOVA) was
used to compare the median pre- and post-vaccination ODs among
all treatment groups [43]. In the event of a signiﬁcant difference,
pairwise comparisons of medians were made using Dunn's multiple comparisons test (among treatments at a given time, and within
a single treatment over time). The data were not treated as repeated
measures because treatment was applied between the ﬁrst and
second sampling times and sample sizes were unequal among
treatments and within treatments over time.
Positive/negative thresholds for each ELISA were set to maximize sensitivity and speciﬁcity. Receiver operator characteristic

(ROC) graphs were generated [43] for each ELISA using threshold
values ranging from the minimum to maximum OD value for the
assay in increments of 0.001. The OD corresponding to the optimum
sensitivity and speciﬁcity was set as the positive/negative threshold
for each assay.
Mean ﬁsh weights and lengths were compared among treatment groups using one-way ANOVA.
Minitab (version 16, Minitab, Inc.; State College, Pennsylvania)
and GraphPad Prism (version 6.07 GraphPad Software; La Jolla,
California) statistical packages for Windows were used for the
above statistical analyses.
3. Results
3.1. Assay positive/negative thresholds
The ROC curves generated for each assay are shown in Fig. 1.
Area under the curve (AUC) corresponds to the probability of a

Table 3
Number of salmon in each treatment group sampled at each time point in the study.
Treatment Group

Pre-vaccination

8 wk Post-vacc.

12 wk Post-vacc.

0
1
2
3
4
5
6
7
8

56
56
55
56
56
56
56
56
56

51
49
51
51
51
43
47
51
50

48
46
49
46
43
42
43
49
48

TOTAL

503

452

418

Fig. 1. ROC curves; the solid line from (0,0) to (1,1) represents a 50% chance of positive
classiﬁcation of a positive or negative sample.
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randomly selected vaccinate being classiﬁed as positive compared
to a randomly selected non-vaccinate receiving the same classiﬁcation using the same assay with a ﬁxed threshold [44]. The AUC for
KLH was calculated to be 0.8930, suggesting that the assay does an
excellent job discriminating between positives and negatives. The
AUCs for the BSA and peptide assays were much lower at 0.5348
and 0.5648, respectively.
The optimum sensitivity and speciﬁcity for each assay and their
corresponding thresholds, set as the positive/negative thresholds,
are summarized in Table 4.
3.2. LH-b peptide antibody response
Overall, approximately 36% (303/849) of samples from ﬁsh
vaccinated against the peptide were identiﬁed as positive
(regardless of carrier; including 8 and 12 weeks post-vaccination).
This is further broken down by treatment in Fig. 2. For all treatments, the proportion of samples positive for LH-b antibodies was
highest at 12 weeks post-vaccination.
3.3. Carrier proteins antibody response
Approximately 96% (361/376) of samples from ﬁsh vaccinated
against KLH and 76% (282/371) of samples from ﬁsh vaccinated
against BSA were identiﬁed as positive for antibodies to the
respective carrier protein. The proportion of positive samples was
highest at 12 weeks post-vaccination for both carrier proteins.
The proportion of samples classiﬁed as positive are shown
further broken down by treatment group to compare performance
of the formulations (Figs. 3 and 4). High background levels in the
anti-BSA and anti-peptide ELISAs are revealed by the large proportion of samples in treatment 0 that are classiﬁed as positive,
despite the control group ﬁsh never having been vaccinated against
these antigens. A dashed line extends horizontally from the top of
the control group's bar to show the misclassiﬁcation rate associated
with the assay at its positive/negative threshold.

Fig. 2. Proportion of samples classiﬁed as positive for antibodies to LH-b peptide;
Treatments 1 through 8 contained the LH-b peptide. Treatment 0 was a sham vaccine
included as a control. 8 and 12 week post-vaccination samples are grouped together
and represented by a single bar for each treatment. A dashed line extends horizontally
from the top of the treatment 0 bar as an approximation of the misclassiﬁcation rate
associated with the assay at its positive/negative threshold. (Treatment carrier protein/
immunostimulant content: 1: BSA/b-glucan, 2: KLH/b-glucan, 3: BSA/muramyl
dipeptide, 4: KLH/muramyl dipeptide, 5: BSA/A. salmonicida þ V. anguillarum, 6: KLH/
A. salmonicida þ V. anguillarum, 7: BSA/M. marinum, 8: KLH/M. marinum).

3.4. Comparison of immunostimulants
Prior to vaccination, there was no signiﬁcant difference in median BSA or KLH antibody levels among treatment groups
(p ¼ 0.707, 0.996 respectively).
No signiﬁcant difference was detected in median BSA antibody
levels among treatment groups at 8 weeks post-vaccination
(p ¼ 0.171). However, a statistically signiﬁcant difference in the
median BSA antibody response was detected at 12 weeks postvaccination (p < 0.0001); by this time, the median BSA antibody
level of treatment group 5 was signiﬁcantly different from that of
all other groups except treatment 3 (p < 0.05) (Fig. 5, Table 5).
Interestingly, treatment 5 was the only one that produced a signiﬁcant difference between pre-vaccination and post-vaccination
BSA antibody levels and this was only seen at 12 weeks postvaccination (p < 0.001).
A statistically signiﬁcant difference in the median KLH antibody
response was detected among treatment groups at 8 and 12 weeks
post-vaccination. All treatment groups vaccinated against KLH had

Table 4
Summary of values for maximum sum of sensitivity and speciﬁcity, corresponding
positive/negative threshold, and individual sensitivity and speciﬁcity.
Antigen

Max Sum

Threshold (OD)

Sensitivity

Speciﬁcity

BSA
KLH
LH

1.0894
1.6951
1.1654

0.0633974
0.168481013
0.012

0.2776
0.7686
0.2603

0.8118
0.9265
0.9051

Fig. 3. Proportion of samples classiﬁed as positive for anti-BSA antibodies; Treatments 1, 3, 5, and 7 contained BSA. 8 and 12 week post-vaccination samples are
grouped together and represented by a single bar for each treatment. The horizontal
dashed line shows the misclassiﬁcation rate associated with the assay at its positive/
negative threshold. (Treatment carrier protein/immunostimulant content: 1: BSA/bglucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).

median responses that were signiﬁcantly different than those of the
non-vaccinates (Fig. 6, Table 6). There was a signiﬁcant difference
between median pre-vaccination and post-vaccination (both 8 and
12 weeks) KLH antibody levels in all four treatment groups vaccinated with KLH (p < 0.001). The 8 week and 12 week postvaccination median KLH antibody responses were signiﬁcantly
different from each other in only two treatment groups, 2 and 6
(p < 0.05).
Prior to vaccination, there was a signiﬁcant difference in median
LH-b antibody levels between treatment groups 1 and 5 (p < 0.01;
treatment 1 sum of ranks and mean of ranks greater than treatment
5). This leveled out by 8 weeks post-vaccination and no signiﬁcant
difference was detected in the median LH-b antibody responses
among treatment groups at this time (p ¼ 0.210). However, a statistically signiﬁcant difference in the median LH-b antibody
response was detected at 12 weeks post-vaccination (p < 0.0001)
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Fig. 4. Proportion of samples classiﬁed as positive for anti-KLH antibodies;
Treatments 2, 4, 6, and 8 contained KLH. 8 and 12 week post-vaccination samples are
grouped together and represented by a single bar for each treatment. The horizontal
dashed line shows the misclassiﬁcation rate associated with the assay at its positive/
negative threshold. (Treatment carrier protein/immunostimulant content: 1: BSA/bglucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).

Fig. 6. Median KLH antibody production over time; treatments 2, 4, 6, and 8 contain
KLH; group 6 anti-KLH levels are the highest at 8 and 12 weeks post-vaccination, but
treatments 2, 4, and 8 also have elevated antibody levels compared to the groups
which were not vaccinated against KLH. (Treatment immunostimulant content: 2: bglucan, 4: muramyl dipeptide, 6: A. salmonicida þ V. anguillarum, 8: M. marinum).

between 8 and 12 weeks post-vaccination (p < 0.001).
3.5. Adjuvant suitability
There was not a signiﬁcant difference in mean ﬁsh length among
treatment groups at any of the three time points (p ¼ 0.214, 0.178,
0.260 for pre-vaccination, 8 weeks, and 12 weeks post-vaccination,
respectively). Similarly, no signiﬁcant difference in mean ﬁsh
weight was detected among treatment groups at any time
(p ¼ 0.158, 0.154, 0.080 for pre-vaccination, 8 weeks, and 12 weeks
post-vaccination, respectively).
4. Discussion

Fig. 5. Median BSA antibody production over time; treatments 1, 3, 5, and 7 contain
BSA; treatment group 5 shows a signiﬁcant increase from 8 weeks to 12 weeks postvaccination. (Treatment immunostimulant content: 1: b-glucan, 3: muramyl dipeptide,
5: A. salmonicida þ V. anguillarum, 7: M. marinum).

when treatment groups 5 and 6 were different from the control
group (p < 0.01) (Fig. 7, Table 7). Additionally, the median LH-b
antibody response of treatment group 5 was signiﬁcantly different
from that of groups 2, 3, and 4 at 12 weeks post-vaccination.
Treatments 1 and 7 produced a signiﬁcant jump in median LH-b
antibody production from 8 weeks to 12 weeks post-vaccination
(p < 0.001, p < 0.05 respectively) while treatment 8 had a signiﬁcant difference between pre-vaccination and 12 week postvaccination levels (p < 0.01). Treatments 5 and 6 produced a signiﬁcant difference in median LH-b antibody response between prevaccination and 12 weeks post-vaccination (p < 0.001) and

The ﬁndings of this study lay the foundation for further research
on development of contraceptive vaccines for Atlantic salmon and
indicate that a hapten-protein conjugate could be functional as a
vaccine antigen in this species. This study also reafﬁrms the value of
selecting an appropriate immunostimulant to enhance the immune
response to a vaccine antigen.
Antibody response to the LH-b peptide was low in both
magnitude and the proportion of positive samples. A simple option
for improving antibody response to the peptide may be to administer a boost dose of the vaccine. Drennan et al. [27] observed
minimal and inconsistent antibody responses in white sturgeon
(Acipenser transmontanus R.) vaccinated against a hapten-protein
antigen. However, after administering a boost dose of the vaccine,
a 16-fold titer increase was observed and the response rate jumped
to 100%. Similarly, rainbow trout (Onchorynkus mykiss) vaccinated
with a ﬂuorescein isothiocyanate-KLH conjugate had low serum
antibody levels that were not differentiable from the control group
until after a booster vaccine was administered [38]. In most species,
a boost dose administered at the appropriate time has been
observed to have this enhancing effect on antibody production and

Table 5
BSA antibody production over time (presented as median adjusted ODs).
Pre-vaccination
Trt
0, 2, 4, 6, 8
1
3
5
7

8 wk Post-vaccination

12 wk Post-vaccination

Median OD

StDev

n

Median OD

StDev

n

Median OD

StDev

n

0.010
0.009
0.004
0.013
0.015

0.049006
0.053386
0.024170
0.046256
0.081633

217
56
52
55
52

0.002
0.009
0.003
0.001
0.010

0.074969
0.055603
0.035719
0.071625
0.152953

194
52
48
38
44

0.009
0.018
0.003
0.064
0.020

0.131198
0.080978
0.066019
0.327983
0.200036

180
48
51
42
48
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Table 6
KLH antibody production over time (presented as median adjusted ODs).
Trt

0, 1, 3, 5, 7
2
4
6
8

Pre-vaccination

8 wk Post-vaccination

12 wk Post-vaccination

Median OD

StDev

n

Median OD

StDev

n

Median OD

StDev

n

0.012
0.007
0.002
0.019
0.013

0.0661714
0.0530410
0.0599784
0.0705586
0.0593099

274
55
55
56
56

0.011
0.185
0.155
0.675
0.145

0.073484
0.443164
0.456520
0.736036
0.324416

245
49
51
45
47

0.018
0.991
0.553
2.450
0.539

0.097673
0.899854
0.799839
0.922341
0.782617

238
50
43
43
48

Fig. 7. Median LH-b peptide antibody production over time; treatments 1 through 8
contain peptide; groups 5 and 6 have the highest median antibody levels 12 weeks
post-vaccination. (Treatment carrier protein/immunostimulant content: 1: BSA/bglucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).

resulting protection [45]. Despite the known beneﬁts of boosting, it
is desirable to achieve efﬁcacy through a single vaccination due to
the cost of vaccines and manpower required to administer those
vaccines to ﬁsh [46]. Additionally, the stress of being handled and
vaccinated takes a toll on ﬁsh health so minimizing the number of
different vaccines necessary is advantageous [26]. Nevertheless, a
multiple vaccination scheme should not be ruled out until costbeneﬁt analyses are conducted.
Treatments 5 and 6, which both contained A. salmonicida and
V. anguillarum as the immunostimulant, produced the strongest
antibody responses to both carrier proteins, and to the LH-b peptide. Using multiple strains of whole bacteria as a vaccine immunostimulant makes sense due to the number of different PAMPs
presented. In ﬁsh, PAMPs have been shown to elevate white blood
cell counts [30,47], stimulate non-speciﬁc immune mechanisms
[26,33], increase antigen uptake [34], enhance activation of
numerous immune components including granulocyte activity, and
increase resistance to infection from several bacterial pathogens
[30,33]. It is also possible that the enhanced antibody response

observed may be partially attributed to an overall increase in antibodies, including those produced against the insoluble bacterial
immunostimulants. It is worth noting that all four of the immunostimulants evaluated were insoluble bacteria or their derivatives,
all of which would theoretically elicit an antibody response. Future
studies should include groups of ﬁsh vaccinated with each individual vaccine component to evaluate respective contributions to
the overall antibody response.
KLH was the strongest immunogen with the majority of ﬁsh
responding positively to this carrier protein. The larger molecular
size of KLH relative to BSA may have contributed to its superior
immunogenicity in Atlantic salmon. However, there was not a
statistically signiﬁcant difference in the LH-b peptide response
between the BSA and KLH carrier groups; the enhanced KLH antibody response was not accompanied by a corresponding increase in
the LH-b response, indicating that both carrier proteins are suitable
for use in this particular application. This also suggests that, relative
to BSA, the stronger antibody response to KLH did not mask or
overwhelm the LH-b peptide antibody response. Within the parameters evaluated in the present study, it appears that the
immunostimulant choice has greater inﬂuence on the LH-b antibody response than does the choice of carrier protein.
Within treatment groups, there appears to be an association
between having a strong antibody response and having a large
proportion of responders. Interestingly, the proportion of responders to KLH was signiﬁcantly higher than that for BSA at both 8
and 12 weeks post-vaccination. The treatments with the largest
proportion of responders and strongest antibody responses for the
carrier proteins also had the highest proportion of responders to
the LH-b peptide. There was a great deal of variation in antibody
response among ﬁsh. Standard deviation was higher among vaccinates than among non-vaccinates.
The anti-BSA and anti-LH-b ELISAs provided predictive capability greater than random chance and allowed for rudimentary
statistical comparison of the various treatments. In maximizing the
sum of sensitivity and speciﬁcity, a large trade-off between the two
was observed, particularly for BSA and LH-b which had low AUCs.
This is not unexpected due to the nature of the relationship between sensitivity and speciﬁcity, but it does lead to low true

Table 7
LH-b peptide antibody production over time (presented as median adjusted ODs).
Trt

0
1
2
3
4
5
6
7
8

Pre-vaccination

8 wk Post-vaccination

12 wk Post-vaccination

Median OD

StDev

n

Median OD

StDev

n

Median OD

StDev

n

0.002
0.001
0.001
0.001
0.000
0.003
0.002
0.001
0.001

0.009880
0.004308
0.010397
0.005855
0.005869
0.011769
0.009447
0.007395
0.007682

53
56
55
53
59
59
56
55
54

0.003
0.002
0.001
0.001
0.001
0.001
0.000
0.001
0.001

0.019656
0.011115
0.010483
0.014000
0.008323
0.074170
0.026871
0.042935
0.155469

48
51
50
51
51
42
53
47
46

0.002
0.002
0.001
0.001
0.000
0.019
0.010
0.004
0.003

0.020910
0.074569
0.034649
0.137381
0.019441
0.205364
0.230183
0.090234
0.206755

48
49
47
46
41
36
48
49
46
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positive rates for these assays while the true negative rates are very
high. Further optimization of these assays may be necessary in
future studies in order to provide improved differentiation between
true and false positives.
Since response rates were greatest at 12 weeks post-vaccination
and the study was terminated at that time, it is not possible to
ascertain whether peak antibody production was reached during
the span of the study. It will be necessary to conduct future trials in
a manner that allows for determination of time post-vaccination
when peak antibody production occurs for each antigen.
Fish weight and length were tracked to ensure that the vaccine
antigens did not adversely affect growth and to evaluate tolerability
to the Montanide ISA 761 VG adjuvant. None of the ﬁsh developed
gross lesions at the vaccine injection site and none of the ﬁsh
deaths that occurred during the study can be deﬁnitively attributed
to vaccination; most of the ﬁsh that died appeared to have suffered
nerve damage resulting from complications during blood sampling.
These observations do not provide any reason to suspect that the
adjuvant used in the study caused any adverse effects. The Montanide ISA 761 VG adjuvant appeared to be well tolerated by the
salmon but additional studies will be necessary to further evaluate
any potential side effects not externally visible and to assess growth
rate relative to an unvaccinated group.
The effects of vaccination on the reproductive physiology and
hormone production of the ﬁsh were not evaluated. Sambroni et al.
[14] vaccinated rainbow trout with phages displaying LH and FSH
receptors, resulting in speciﬁc antibody production, reduced hormone levels, and delayed spermiation and vitellogenesis, suggesting that disruption of this signaling pathway could prevent sexual
maturation of Atlantic salmon. Antibody responses are not always
predictive or correlative to the physiological effects of vaccination,
especially with immunocontraceptives, so a longer study duration
and evaluation of additional reproductive metrics is necessary. This
would be especially useful to determine whether any delay in
sexual maturation had positive outcomes related to improved body
condition and mass.
The ﬁndings of this study indicate that it is possible to stimulate
the immune system of Atlantic salmon to produce antibodies
against a small endogenous peptide conjugated to a carrier protein.
It was determined that KLH and BSA perform comparably as hapten
carriers and that an immunostimulant combining A. salmonicida
and V. anguillarum provides an improved antibody response. The
proportion of positive samples and antibody levels were highest at
12 weeks post-vaccination suggesting that the water-in-oil vaccine
provides a potentially extended release of antigen, possibly due to
granuloma formation as observed by Evensen et al. [48] or persistent active inﬂammation [49]. Further research will be necessary to
improve the formulation of the contraceptive vaccine candidates
and determine the physiological signiﬁcance of the resulting
antibodies.
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